You are here

Article Text

Article menu
Download PDFPDF
DTB select
Risk of serious adverse effects with Janus kinase inhibitors

Abstract

Overview of: European Medicines Agency. EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. November 2022.

  • Health Care Quality, Access, and Evaluation
  • Drug-Related Side Effects and Adverse Reactions

https://doi.org/10.1136/dtb.2022.000078

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors DTB Team.

    • Provenance and peer review Commissioned; internally peer reviewed.